The effect of cannabidiol in facilitating fear extinction and in attenuating fear retention and reinstatement in humans

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 56

Inclusion Criteria

- Male or female volunteers between 18 and 30 years.
- Judged to be in good physical and mental health on the basis of the medical history according to self-report.
- Have a normal binocular acuity, corrected or uncorrected.
- Female participants must declare they are on reliable birth control.

Exclusion Criteria

- History of any disease, e.g. neurological disorders, psychiatric disorders, which in the opinion of the investigator may confound the results of the study.
- Present any other conditions in that in the investigators*, the subjects* personal or the study physicians* opinion may confound the results of the study.
- History of psychotic disorder/psychosis and/or having a first/second degree family member with (a history of) psychotic disorder/psychosis.
- Current diagnosis of an Axis I or Axis II psychiatric disorder, or suffering from an Axis I or Axis II psychiatric disorder within 4 weeks prior to the study.
- Current cardiac disease and/or history of cardiac disease.
- Known hypersensitivity to CBD.
- History of cannabinoids exopsure with adverse reactions.
- History of severe allergy or general drug hypersensitivity.
- History of abuse or current regular use of cannabis more than once a week.
- Usage of psychoactive drugs in the four weeks prior to the study.
- Current use of drugs of abuse or indications (urine screening)
- History of epilepsy.
- Pregnancy, i.e., a positive *-HCG urine test.
- Lactating.
- Reduced startle reactivity, defined as no discernable response in at least 3 out of the 12 startle stimuli presented at screening.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Fear as reflected in the EMG and SCR amplitude and as reflected in answers on a<br /><br>VAS during a passive VR navigation task (see protocol [C1] for details).</p><br>

Secondary Outcome Measures